Solid Biosciences Inc. (SLDB) Cash Flow Statement

The ratio of operating cash flow to net income has been volatile, dipping to 0.73 in 2025Q3 and 0.70 in 2024Q4, suggesting that reported losses understate cash outflows. Stock-based compensation, which rose from $1.6M in 2024Q1 to $5.6M in 2026Q2, adds back to net income but does not represent cash, yet the cash burn still exceeds net losses in several quarters, implying aggressive working capital consumption or other cash-draining items. This divergence warrants close monitoring as the company advances SGT-003.

The quarterly FCF deficit has more than doubled over the observed period, with the most recent quarter showing a burn of $52.7M, up from $21.8M in 2024Q2. This acceleration aligns with the strategic pivot to SGT-003, which appears to be driving higher R&D and manufacturing costs. Given the $59.9M cash position, the current burn rate suggests a runway of roughly one year, assuming no additional capital inflows, which may force dilutive financing or partnership restructuring.

CapEx has been consistently low, ranging from $15K to $565K per quarter, which is typical for a clinical-stage biotech that outsources manufacturing. The lack of significant capital investment suggests that the company's growth strategy relies on external manufacturing capacity, which may expose it to supply chain risks and higher variable costs. Investors should monitor whether future commercial-scale production will require substantial capex, which could further strain liquidity.

The working capital adjustments have been erratic, with a notable outflow of $13.2M in 2025Q4 and an inflow of $7.2M in 2025Q3, suggesting timing differences in payments and receipts. These swings may reflect prepayments for manufacturing slots or milestone payments from collaborations, which can distort quarterly cash flow comparisons. Analysts should adjust for these items to assess the underlying operational burn, which appears to be trending higher.

The buyback activity is notable given the cash constraints, with $12.9M spent in 2026Q2 and a smaller repurchase in 2024Q3, while no dividends have been paid. This deployment of scarce capital could be seen as a signal of confidence, but it also reduces the cash runway at a critical juncture. Given the negative ROE of -109.9%, the buyback may not be the most efficient use of funds, and investors should question whether this is a prudent allocation.

The cumulative gap of $54.4M between net income and operating cash flow suggests that a significant portion of reported losses is non-cash, primarily stock-based compensation, which totaled $38.1M over the period. This divergence implies that the company's cash burn is somewhat lower than the accounting losses, but the trend is still alarming given the accelerating burn rate. The cumulative cash outflow of $356.2M underscores the heavy capital requirements of gene therapy development, and the company's ability to secure additional funding remains a critical risk.